Always in the best of spirits and with a very strong faith, Jamon Tavio King is facing a battle with a very rare leukemia […] ...

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...

HBV coinfection with acute exacerbation was associated with significantly worse survival outcomes in pediatric T-ALL.

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Some researchers trained the immune systems of leukemia patients to help keep them in remission. And other researchers found ...